Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy
Latest Information Update: 14 Jul 2022
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms LIGHT
- Sponsors AstraZeneca
- 05 Jul 2022 Phase II LIGHT study primary analysis results published in the Gynecologic Oncology
- 07 Jun 2022 Results of targeted circulating tumor DNA (ctDNA) sequencing analyzed over 500 plasma samples collected at baseline and at progression to therapy in one of three Phase II/III clinical studies (LIGHT NCT02983799, SOLO3 NCT02282020, OlympiAD NCT02000622) presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results (data cut off : Aug 27, 2020) of overall survival analyses presented at the 57th Annual Meeting of the American Society of Clinical Oncology